• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Sebetralstat improves symptom relief in acute hereditary angioedema attacks

byJessie WillisandTeddy Guo
February 22, 2023
in Chronic Disease, Emergency, Rheumatology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. An oral dose of sebetralstat increased the time to conventional treatment use and lead to faster symptom relief in acute hereditary angioedema attacks compared to control.

2. Sebetralstat was well tolerated and was demonstrated to rapidly reduce activity of plasma kallikrein.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hereditary angioedema is a rare disease that causes episodic attacks of tissue swelling. Current treatments include on-demand and prophylactic medications, but these are parenterally administered. This phase 2 drug study aims to evaluate the use of an oral plasma kallikrein inhibitor, sebetralstat, for the on-demand treatment of angioedema attacks. This study had two parts. Part 1 was a safety, pharmacokinetics, and pharmacodynamics assessment where all enrolled patients received the study drug of 600 mg oral sebetralstat after the screening. The drug was found to be well tolerated and led to rapid suppression of plasma kallikrein activity. In Part 2, the participants were randomized to either sequence 1 (sebetralstat, then placebo) or sequence 2 (placebo, then sebetralstat). In summary, the time to conventional treatment usage within 12 h of the study drug administration was significantly longer with sebetralstat versus placebo. In addition, symptom relief was much faster with the use of sebetralstat versus placebo. There were no serious adverse events. Limitations of this study include the within-participant dependence of endpoints due to the crossover. Nevertheless, this study shows promising early results for the safety and efficacy of sebetralstat. A larger confirmatory phase 3 trial is currently underway.

Click to read the study in The Lancet

Relevant Reading: Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema

RELATED REPORTS

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

In-Depth [randomized controlled trial]: This international phase 2 drug trial evaluated the use of a novel oral plasma kallikrein inhibitor, sebetralstat, for the on-demand treatment of acute flares of hereditary angioedema. Eligible participants were aged over 18 years old and had a confirmed diagnosis of hereditary angioedema type 1 or 2 with three or more attacks in the past 93 days. Life-threatening attacks, such as laryngeal or facial attacks, were also excluded due to safety. The mean age of the enrolled participants (n=68) was 38.3 years and 54% were female. In part 1, all participants were given sebetralstat as a single oral dose within 28 days of their screening visit. In part 2, participants were randomized 1:1 to either sequence 1 (600 mg sebetralstat, then placebo) or sequence 2 (placebo, then 600 mg sebetralstat). For example, in sequence 1, patients were to self-administer 600 mg sebetralstat after their first attack and placebo after their second attack. The primary endpoint for part 2 was time to use of conventional attack treatment within 12 h of study drug administration.

Part 1 was a safety, pharmacokinetics, and pharmacodynamics assessment which 42 (62%) of 68 participants completed. The drug was well tolerated and demonstrated evidence of rapid suppression of plasma kallikrein activity. In part 2, the time to use conventional treatment was significantly longer with sebetralstat versus placebo (at quartile 1: >12 h [95% CI 9.6 to >12] versus 8.0 h [3.8 to >12]; p=0.0010). Time to symptom relief was additionally faster with sebetralstat compared to placebo (1.6 h [1.5 to 3.0] versus 9.0 h [4.0 to 17.2]; p<0.0001). No drug-related serious adverse events or discontinuations were recorded.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemabradykininhereditary angioedemakallikreinsebetralstatswelling
Previous Post

Recommendations for opioid use in the management of chronic pain

Next Post

Dietary insoluble fiber intake may be associated with lower risk of hypertension

RelatedReports

Pharma

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks

November 25, 2024
#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema
StudyGraphics

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

August 13, 2024
#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks
StudyGraphics

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

July 31, 2024
Chronic Disease

Oral sebetralstat provides early symptom relief for hereditary angioedema attacks

July 15, 2024
Next Post
Diet and nutrition collage: a plate of greens, tomato, chickpeas, walnuts and whole-grain bread with a fork and olive oil

Dietary insoluble fiber intake may be associated with lower risk of hypertension

New AAP guidelines against albuterol for bronchiolitis

RSV prefusion F protein vaccine is safe and effective in preventing RSV infection

BNT162b2 COVID-19 vaccine safe and efficacious in young children

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind November 16, 2026
  • ERX1000 plus semaglutide increased weight loss and metabolic measures in diet-induced obese mice
  • Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.